← Back to Search

Procedure

AURORA for Hemorrhage (MIRROR Trial)

N/A
Recruiting
Led By Christopher Kellner, MD
Research Sponsored by Integra LifeSciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during surgical procedure to evacuate supratentorial intracerebral hemorrhage
Awards & highlights

Summary

This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery from last known well time will be explored.

Eligible Conditions
  • Hemorrhage

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during surgical procedure to evacuate supratentorial intracerebral hemorrhage
This trial's timeline: 3 weeks for screening, Varies for treatment, and during surgical procedure to evacuate supratentorial intracerebral hemorrhage for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of Surgical Success

Trial Design

1Treatment groups
Experimental Treatment
Group I: AURORAExperimental Treatment1 Intervention
Aurora® Surgiscope used for MIS evacuation of supratentorial hematoma

Find a Location

Who is running the clinical trial?

Integra LifeSciences CorporationLead Sponsor
107 Previous Clinical Trials
10,942 Total Patients Enrolled
2 Trials studying Hemorrhage
359 Patients Enrolled for Hemorrhage
Icahn School of Medicine at Mount SinaiOTHER
886 Previous Clinical Trials
534,543 Total Patients Enrolled
6 Trials studying Hemorrhage
19,162 Patients Enrolled for Hemorrhage
Oculus Imaging LLCUNKNOWN
~253 spots leftby Oct 2028